Advances in adenovirus-mediated p53 cancer gene therapy

@article{Tazawa2013AdvancesIA,
  title={Advances in adenovirus-mediated p53 cancer gene therapy},
  author={Hiroshi Tazawa and Shunsuke Kagawa and Toshiyoshi Fujiwara},
  journal={Expert Opinion on Biological Therapy},
  year={2013},
  volume={13},
  pages={1569 - 1583}
}
Introduction: The tumor suppressor p53 gene regulates diverse cellular processes, such as cell-cycle arrest, senescence, apoptosis and autophagy, and it is frequently inactivated by genetic alterations in ∼ 50% of all types of human cancers. To restore wild-type p53 function in p53-inactivated tumors, adenovirus-mediated p53 gene therapy has been developed as a promising antitumor strategy in preclinical experiments and clinical studies. Areas covered: This review focuses on the clinical… 
p53 Replacement Therapy for Cancer.
  • H. Tazawa, S. Kagawa, T. Fujiwara
  • Medicine
    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer
  • 2016
TLDR
This chapter focuses on four types of p53 transfer systems: cationic liposome-DNA plasmid complexes, a replication-deficient adenovirus vector, a replicated-competent adenova vector, and a protein transduction system.
Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives
TLDR
The biological mechanisms, clinical utility, and therapeutic potentials of the replication-deficient Adp53-based and replication-competent CR adenoviral vectors used in gene therapy are discussed.
A novel approach to glioma therapy using an oncolytic adenovirus with two specific promoters.
TLDR
Exogenous expression of functional p53 and that of E1A may increase the potency of CRAd, and overexpression of p53 through CRAd is a promising approach to more effective treatments in a number of human cancer types.
Tumor suppressor p53 and its gain-of-function mutants in cancer.
TLDR
The mechanisms of p53 in tumor suppression and gain-of-function mutant p53 oncogenic activities in tumor development are reviewed, as well as the recent advances in the development of the p53-based tumor therapy.
Key points of basic theories and clinical practice in rAd-p53 (Gendicine™) gene therapy for solid malignant tumors
TLDR
The key points of the drug administration were discussed, including the routes of administration, dosage calculation and treatment cycles, based on findings of the preclinical and clinical trials in order to establish a standard treatment for the p53 gene therapy.
Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells
TLDR
It is found that shRNA-58335 evokes the apoptotic response following p53 transduction or functional restoration of p53 with a small molecule drug in cancer cells resistant to p53-induced apoptosis.
p53 as a target for the treatment of cancer.
Bone and Soft-Tissue Sarcoma: A New Target for Telomerase-Specific Oncolytic Virotherapy
TLDR
Taken together, telomerase-specific oncolytic adenoviruses are promising antitumor reagents that are expected to provide novel therapeutic options for the treatment of bone and soft-tissue sarcomas.
Chemical Variations on the p53 Reactivation Theme
TLDR
An updated overview of the most relevant small molecules developed to restore p53 function in cancer cells through inhibition of the p53-MDMs interaction, or direct targeting of wild-type p53 or mutated p53 will be presented.
Status quo of p53 in the treatment of tumors
TLDR
The review focuses on the available technological protocols, including their advantages and limitations in terms of future therapeutic use of p53 in the management of tumors, and investigates individualized p53 therapy.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 111 REFERENCES
A Single Recombinant Adenovirus Expressing p53 and p21-targeting Artificial microRNAs Efficiently Induces Apoptosis in Human Cancer Cells
TLDR
An adenovirus vector that expresses p53 and suppresses p21 simultaneously to enhance p53-mediated apoptosis is developed and suggests thatAd-p53/miR-p21-specific microRNAs may be useful for gene therapy of human cancers.
p53-based cancer therapy.
TLDR
Increased understanding of the p53 response is allowing the development of powerful drug combinations that may increase the selectivity and safety of chemotherapy, by selective protection of normal cells and tissues.
Adenovirus-mediated p53 gene therapy for human cancer.
TLDR
The p53 tumor suppressor gene has been implicated in many inherited and sporadic forms of malignancies in humans and has entered clinical testing and provided intriguing information about the intratumoral administration of an adenovirus vector expressing the wildtype p53 gene in non-small-cell lung cancer.
Adenovirus-mediated p53 tumor suppressor gene therapy of osteosarcoma
The clinical outcome for osteosarcoma (OS) remains discouraging despite efforts to optimize treatment using conventional modalities including surgery, radiotherapy and chemotherapy. Novel therapeutic
In vivo adenovirus-mediated p53 tumor suppressor gene therapy for colorectal cancer.
TLDR
Significant suppression of in vitro cell proliferation and induction of apoptosis were observed following Ad5/CMV/p53 infection and similar effects were observed in vivo in an established nude mouse subcutaneous tumor model.
Adenovirus-mediated p53 gene therapy inhibits human sarcoma tumorigenicity
TLDR
Results indicate that wild-type p53 gene restoration in sarcomas retards tumor growth and may come to be usefully applied to the clinical treatment of this disease as a single regimen or in combination with conventional therapies.
A novel triple-regulated oncolytic adenovirus carrying p53 gene exerts potent antitumor efficacy on common human solid cancers
TLDR
It is concluded that the triple-regulated SG600-p53, as a more potent and safer antitumor therapeutic, could provide a new strategy for cancer biotherapy.
Adenovirus-mediated p53 gene therapy for human gliomas.
TLDR
Preclinical data strongly support the use of p53 gene transfer as a potential treatment for human gliomas, and the main obstacle to p 53 gene therapy involves the limitations associated with current modes of delivery.
Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer.
TLDR
Results indicate that transfection of cervical cancer cells with the wild-type p53 gene via Ad5CMV-p53 is a potential novel approach to the therapy of cervical cancers.
Adenovirus-based p53 gene therapy in ovarian cancer.
TLDR
The ability of the adenovirus vector to mediate high-level expression of infected genes and the inhibitory effect of Ad-CMV-p53 on the 2774 cell line suggests that the Ad- CMV- p53 could be further developed into a therapeutic agent for ovarian cancer.
...
1
2
3
4
5
...